Optimal proteinuria target for renoprotection in patients with IgA nephropathy

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Nam, Ki Heon ^a   Kie, Jeong Hae ^b   Lee, Mi Jung ^a   Chang, Tae Ik ^b   Kang, Ea Wha ^b   Kim, Dong Wook ^a   Lim, Beom Jin ^a   Park, Jung Tak ^a   Kwon, Young Eun ^a   Kim, Yung Ly ^a   Park, Kyoung Sook ^a   An, Seong Yeong ^a   Oh, Hyung Jung ^a   Yoo, Tae Hyun ^a   Kang, Shin Wook ^a   Choi, Kyu Hun ^a   Jeong, Hyeon Joo ^a   Han, Dae Suk ^a   Han, Seung Hyeok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Health Insurance Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; CREATININE URINE LEVEL; DISEASE DURATION; DISEASE SEVERITY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; GLOMERULONEPHRITIS, IGA; KAPLAN MEIER METHOD; KIDNEY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ADULT; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903892489     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101935     Document Type: Article

References (30)

1. Barratt J, Feehally J (2005) IgA nephropathy. J Am Soc Nephrol 16: 2088-2097.
2. Berthoux FC, Mohey H, Afiani A (2008) Natural history of primary IgA nephropathy. Semin Nephrol 28: 4-9.
3. Frimat L, Briancon S, Hestin D, Aymard B, Renoult E, et al. (1997) IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Nephrologues de l'Est. Nephrol Dial Transplant 12: 2569-2575.
4. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, et al. (2011) Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22: 752-761.
5. Radford MG, Jr., Donadio JV, Jr., Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199-207.
6. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, et al. (2003) A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 18: 1541-1548.
7. Li PK, Ho KK, Szeto CC, Yu L, Lai FM (2002) Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol Dial Transplant 17: 64-69.
8. Bartosik LP, Lajoie G, Sugar L, Cattran DC (2001) Predicting progression in IgA nephropathy. Am J Kidney Dis 38: 728-735.
9. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM (2002) Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 17: 1197-1203.
10. Lv J, Zhang H, Chen Y, Li G, Jiang L, et al. (2009) Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 53: 26-32.
11. Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis R (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177-3183.
12. Le W, Liang S, Hu Y, Deng K, Bao H, et al. (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 27: 1479-1485.
13. Coppo R, D'Amico G (2005) Factors predicting progression of IgA nephropathies. J Nephrol 18: 503-512.
14. Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, et al. (2008) The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 23: 2247-2253.
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
16. Working Group of the International Ig ANN, the Renal Pathology S, Roberts IS, Cook HT, Troyanov S, et al. (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556.
17. Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, et al. (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76: 534-545.
18. Radhakrishnan J, Cattran DC (2012) The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient. Kidney Int 82: 840-856.
19. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
20. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al. (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320.
21. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860.
22. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, et al. (2001) Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131-1140.
23. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, et al. (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139: 244-252.
24. Barbour SJ, Reich HN (2012) Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 59: 865-873.
25. Rosselli JL, Thacker SM, Karpinski JP, Petkewicz KA (2011) Treatment of IgA nephropathy: an update. Ann Pharmacother 45: 1284-1296.
26. Gutierrez E, Zamora I, Ballarin JA, Arce Y, Jimenez S, et al. (2012) Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 23: 1753-1760.
27. Hladunewich MA, Troyanov S, Calafati J, Cattran DC, Metropolitan Toronto Glomerulonephritis R (2009) The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 4: 1417-1422.
28. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, et al. (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163.
29. Lv J, Xu D, Perkovic V, Ma X, Johnson DW, et al. (2012) Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23: 1108-1116.
30. Price CP, Newall RG, Boyd JC (2005) Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem 51: 1577-1586.